Nathanael S Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. He received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, he was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six-year stay at GNF, he became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological, and pharmacological approaches towards the development of new experimental drugs. In 2006, he returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. In 2021, he joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H, and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
